| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -50.8% | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 4.5 | n/a |
| Pr/Book | 1.6 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 34.8% | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | 1.37 | (2.55) | (0.66)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-21 | 1.23 | (3.40) | (0.73)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | 1.83 | (2.57) | (0.59)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 3.19 | (6.92) | (1.54)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | 4.30 | (2.18) | (0.36)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Novellus+ Regulatory Authorisation in Chile | 09-Jan-2026 | 07:00 | RNS |
| Mevalone Label Extension in France | 07-Jan-2026 | 07:00 | RNS |
| Appointment of Syngenta as Distribution Partner | 18-Dec-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 3.65p |
| Change Today | 0.050p |
| % Change | 1.39 % |
| 52 Week High | 4.25 |
| 52 Week Low | 2.10 |
| Volume | 389,070 |
| Shares Issued | 533.35m |
| Market Cap | £19.47m |
| Beta | 0.78 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 12:18 | 50,000 @ 3.70p |
| 12:18 | 50,000 @ 3.64p |
| 11:54 | 6,756 @ 3.70p |
| 11:47 | 11,260 @ 3.63p |
| 11:35 | 11,384 @ 3.61p |
| CFO | Alexander John Abrey |
| CEO | Sean M. Smith |
You are here: research